Overview
- 3 public-safe observations are available for this inspection.
- 3 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
9 Sep 2024
21 CFR 111.105(f)
Quality control - representative samples
Cited by Dariusz Galezowski, Roshni J Patel
9 Sep 2024
21 CFR 111.105(i)
Quality control - required operations
Cited by Dariusz Galezowski, Roshni J Patel
9 Sep 2024
21 CFR 111.113(c)
Document - material review, disposition
Cited by Dariusz Galezowski, Roshni J Patel
Inspected site
LRLife Rising CorporationWillowbrook, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 111.105(f) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.105(i) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.113(c) | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 3 observations
The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere